

## **Abzyme to Present at 19<sup>th</sup> PEGS Congress in Boston, Massachusetts**

**Royersford, PA, May 15, 2023.** Abzyme Therapeutics LLC will present at the PEGS' 19<sup>th</sup>, “The Essential Protein Engineering and Cell Therapy Summit,” from May 15 to May 19, 2023, in Boston, Massachusetts. Dr. Hiep Tran, Chief Scientific Officer, will present Abzyme Therapeutic's new data related to progressive multiple sclerosis immunotherapy. His presentation title is “Dual Action Antibodies for Treatment of Progressive Multiple Sclerosis.”

Abzyme Therapeutics has developed two cross-species reactive nanobodies capable of overcoming the blood-brain barrier. The first antibody is a potent complement pathway inhibitor, designed to inhibit antibody-mediated inflammation and cell destruction. The second antibody is an analog to brain-derived neurotrophic factor, BDNF, capable of stimulating nerve cell growth. Therapeutic efficacy of these antibodies was validated in a well-characterized murine model of progressive MS, Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD). Treatment with either one antibody significantly improved the progressive neurological impairment in TMEV-IDD mice. These exciting results were obtained thanks to the funding from the National Institutes of Health under the SBIR grant R43 NS120624-01, in collaboration with Dr. Francesca Gilli, professor of Neurology at Dartmouth College, Hanover, New Hampshire. Abzyme is seeking partners to further validate these antibodies in other CNS disorders, including traumatic brain injuries (TBI) and Alzheimer's Diseases.

### **About Abzyme Therapeutics:**

Abzyme Therapeutics is a biopharmaceutical company focused on antibody discovery and engineering using proprietary antibody generation platforms. Unique to Abzyme is its proprietary and highly engineered eukaryotic *in vitro* antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation, in combination with a FACS single-cell sorting approach to identify desired antibodies. Abzyme's modular antibody discovery platform incorporates a real-time screening ability to select for key properties, such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity. The platforms have been successfully applied to develop antibodies with defined attributes as well as to re-engineer existing antibodies to be conditionally active. Abzyme offers fee-for-services in antibody discovery and engineering, including conditionally active antibodies

Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas, including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.

For further information, please contact:

Abzyme Therapeutics LLC  
Steve Manobianco  
Director of Business Development  
Phone: 610-990-7531  
E-mail: [manobianco@abzymetx.com](mailto:manobianco@abzymetx.com)